Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ovid Therapeutics (OVID) Operating Income (2020 - 2025)

Historic Operating Income for Ovid Therapeutics (OVID) over the last 6 years, with Q3 2025 value amounting to -$12.5 million.

  • Ovid Therapeutics' Operating Income rose 531.53% to -$12.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$40.9 million, marking a year-over-year increase of 4106.82%. This contributed to the annual value of -$61.9 million for FY2024, which is 439.26% down from last year.
  • According to the latest figures from Q3 2025, Ovid Therapeutics' Operating Income is -$12.5 million, which was up 531.53% from -$5.1 million recorded in Q2 2025.
  • In the past 5 years, Ovid Therapeutics' Operating Income registered a high of $176.6 million during Q1 2021, and its lowest value of -$26.4 million during Q4 2021.
  • Moreover, its 5-year median value for Operating Income was -$13.2 million (2024), whereas its average is -$4.3 million.
  • Its Operating Income has fluctuated over the past 5 years, first soared by 96998.11% in 2021, then plummeted by 10921.35% in 2022.
  • Quarter analysis of 5 years shows Ovid Therapeutics' Operating Income stood at -$26.4 million in 2021, then skyrocketed by 53.81% to -$12.2 million in 2022, then tumbled by 49.41% to -$18.2 million in 2023, then soared by 41.05% to -$10.7 million in 2024, then decreased by 16.8% to -$12.5 million in 2025.
  • Its Operating Income stands at -$12.5 million for Q3 2025, versus -$5.1 million for Q2 2025 and -$12.5 million for Q1 2025.